Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7746403 | 1.00 | GPR84 (0.42) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL7746400 | 1.00 | GPR84 (0.42) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL6021146 | 1.00 | GPR84 (0.42) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL6738137 | 1.00 | GPR84 (0.42) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL1276926 | 1.00 | GPR84 (0.42) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL8971316 | 1.00 | GPR84 (0.42) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL10703861 | 0.98 | GPR84 (0.39) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL10534735 | 0.91 | DNM1 (0.33) | GPR84FFAR1MAPTFDPSDNM1 | |
| SCHEMBL9714347 | 0.86 | MAPT (0.46) | GPR84FFAR1MAPTFDPSLMNA | |
| SCHEMBL7167398 | 0.86 | MAPT (0.46) | GPR84FFAR1MAPTFDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686442-B2 | PEPTIDE NUCLEIC ACID FOR USE IN VETERINARY MEDICINE | Neilsen, Peter E. (DK) | 2004-02-03 | — | — | US | disclosed |
| US-20020188101-A1 | Conjugated peptide nucleic acids having enhanced cellular uptake | ISIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| EP-1003480-A4 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN PETER EIGIL (DK) | 2002-04-17 | — | — | EP | disclosed |
| US-6350853-B1 | PEPTIDE NUCLEIC ACIDS CONJUGATED TO LIPOPHILIC GROUP AND HAVING MODIFIED BACKBONE WHEREIN AMINO ACID SIDE CHAIN IS ATTACHED TO BACKBONE | Nielsen, Peter E. (DK) | 2002-02-26 | — | — | US | disclosed |
| EP-1003480-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | NIELSEN, Peter Eigil (DK) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998053801-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5604224-A | NEURODEGENERATIVE DISORDERS | STERLING WINTHROP INC. (US) | 1997-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188101-A1 | Conjugated peptide nucleic acids having enhanced cellular uptake | SLC1A5, SLC7A1, SLC29A1 | GPR84 393/4885FFAR1 400/4885MAPT 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.